{"product_id":"overcoming-obstacles-in-drug-discovery-and-development-surmounting-the-insurmountable-case-studies-for-critical-thinking-paperback-9780128171349","title":"Overcoming Obstacles in Drug Discovery and Development; Surmounting the Insurmountable—Case Studies for Critical Thinking (Paperback) 9780128171349","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eOvercoming Obstacles in Drug Discovery and Development\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eSurmounting the Insurmountable—Case Studies for Critical Thinking\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cem\u003eUses case studies to demonstrate how critical thinking and problem-solving skills are applied in the successful discovery and development of drugs\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eKan He (Edited by), Paul F. Hollenberg (Edited by), Larry C. Wienkers (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780128171349, Elsevier Science\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003ePaperback, published 24 May 2023\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e446 pages\u003cbr\u003e23.5 x 19 x 2.8 cm, 0.45 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003cb\u003e\u003ci\u003eOvercoming Obstacles in Drug Discovery and Development\u003c\/i\u003e\u003c\/b\u003e uses real-world case studies to illustrate how critical thinking and problem solving skills are applied in the discovery and development of drugs. It also shows how developing critical thinking to overcome issues plays an essential role in the process. Modern drug discovery and development is a highly complex undertaking that requires scientific and professional expertise to be successful. After the identification of a molecular entity for treating a medical condition, challenges inevitably arise during the subsequent development to understand and characterize the biological profile; feedback from scientists is used to fine-tune the molecular entity to obtain an effective and safe product. In this process, the discovery team may identify unexpected safety issues and new medical disorders for treatment by the molecular entity. Invariably inherent in this complex undertaking are miscues, mistakes, and unexpected problems that can derail development and throw timetables into disarray, potentially leading to failure in the development of a medically useful drug. Addressing critical unexpected problems during development often requires scientists to utilize critical thinking and imaginative problem-solving skills. \u003cb\u003e\u003ci\u003eOvercoming Obstacles in Drug Discovery and Development\u003c\/i\u003e\u003c\/b\u003e will be essential to young scientists to help learn the skills to successfully face challenges, learn from mistakes, and further develop critical thinking skills. It will also be beneficial to experienced researchers who can learn from the case studies of successful and unsuccessful drug development.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eKan He, Paul Frederick Hollenberg and Larry C. Wienkers\u003c\/p\u003e \u003cp\u003e1. Learning to think critically\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eBrian Barnes \u003c\/p\u003e \u003cp\u003e2. Leveraging ADME\/PK information to enable knowledge-driven decisions in drug discovery and development\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eLarry C. Wienkers\u003c\/p\u003e \u003cp\u003e3. Systems biology and data science in research and translational medicine\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eKarim Azer, Jeff S. Barrett, Mirjam Trame and Cynthia J. Musante\u003c\/p\u003e \u003cp\u003e4. Drug Discovery and Development of ASO\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eBrooke Rock\u003c\/p\u003e \u003cp\u003e5. Drug development of covalent Inhibitors\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eUpendra P. Dahal and Jan L. Wahlstrom\u003c\/p\u003e \u003cp\u003e6. Denosumab: dosing and drug interaction challenges on the path to approval\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eGraham Jang\u003c\/p\u003e \u003cp\u003e7. Discovery and development of ADCs: obstacles and opportunities\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eHsuan Ping Chang, Yuen Kiu Cheung and Dhaval K. Shah\u003c\/p\u003e \u003cp\u003e8. How to reduce risk of drug induced liver toxicity from the beginning\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eJinping Gan, Kan He and W. Griffith Humphreys\u003c\/p\u003e \u003cp\u003e9. Optimization for small volume of distribution leading to the discovery of apixaban\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eKan He\u003c\/p\u003e \u003cp\u003e10. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eSimon G. Wong and Shuguang Ma\u003c\/p\u003e \u003cp\u003e11. Conquering low oral bioavailability issues in drug discovery and development\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eTimothy J. Carlson\u003c\/p\u003e \u003cp\u003e12. Case study of OATP1B DDI assessment and challenges in drug discovery and development—real-life examples\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eHong Shen, Jinping Gan and Giridhar S. Tirucherai\u003c\/p\u003e \u003cp\u003e13. Investigating the link between drug metabolism and toxicity \u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eW. Griffith Humphreys\u003c\/p\u003e \u003cp\u003e14. Overcoming nephrotoxicity in rats: the successful development and registration of the HIV-AIDS drug efavirenz (Sustiva®)\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eD.D. Christ\u003c\/p\u003e \u003cp\u003e15. Disproportionate drug metabolites: challenges and solutions\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eChandra Prakash\u003c\/p\u003e \u003cp\u003e16. Disposition and metabolism of ozanimod—Surmounting the unanticipated challenge late in the development\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eDeepak Dalvie and Sekhar Surapaneni\u003c\/p\u003e \u003cp\u003e17. Application of reaction phenotyping to address pharmacokinetic variability in patient populations\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eRobert S. Foti, Joseph M. Roesner and Joshua T. Pearson\u003c\/p\u003e \u003cp\u003e18. Kyprolis (carfilzomib) (approved): a covalent drug with high extrahepatic clearance via peptidase cleavage and epoxide hydrolysis\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eZhengping Wang, Jinfu Yang an Christopher Kirk \u003c\/p\u003e \u003cp\u003e19. Engaging diversity in research: Does your drug work in overlooked populations?\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eKaren E. Brown and Erica L. Woodahl\u003c\/p\u003e \u003cp\u003e20. PBPK modeling for Early clinical study decision making\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eArian Emami Riedmaier\u003c\/p\u003e \u003cp\u003e21. Integrated pharmacokinetic\/pharmacodynamic\/efficacy analysis in oncology: importance of pharmacodynamic\/efficacy relationships\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eHarvey Wong\u003c\/p\u003e \u003cp\u003e22. Predicting unpredictable human pharmacokinetics: Case studies from the trenches of drug discovery\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003eZheng Yang\u003c\/p\u003e \u003cp\u003e23.  Esmolol (soft drug design)\u003c\/p\u003e\n\u003ci\u003e \u003c\/i\u003e\u003cp\u003ePaul W. Erhardt\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Pharmacology [\u003ca title=\"See our other books on Pharmacology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Pharmacology%20%5BMMG%5D%22\"\u003eMMG\u003c\/a\u003e], Pharmaceutical industries [\u003ca title=\"See our other books on Pharmaceutical industries\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Pharmaceutical%20industries%20%5BKNDP%5D%22\"\u003eKNDP\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Academic Press","offers":[{"title":"Default Title","offer_id":46650087309592,"sku":"9780128171349","price":85.49,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/products\/9780128171349.jpg?v=1694105790","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/overcoming-obstacles-in-drug-discovery-and-development-surmounting-the-insurmountable-case-studies-for-critical-thinking-paperback-9780128171349","provider":"Freshly Printed Books","version":"1.0","type":"link"}